BACKGROUND: Disability and frailty are associated with osteoporosis, obesity, and sarcopenia. HIV-infected persons have early functional impairment, but the association between body composition and functional impairment is unknown. METHODS: HIV-1-infected participants on combination antiretroviral therapy with virologic suppression, aged 45-65 years, had standardized physical function measures. In a nested analysis, 30 low- and 48 high-functioning cases and controls were matched by age, gender, and time since HIV diagnosis. Bone mineral density, fat mass, and lean body mass were assessed by dual-energy x-ray absorptiometry. Odds ratios (ORs) with 95% confidence intervals were obtained from conditional logistic regression. RESULTS: Mean age was 53 years, mean CD4(+) lymphocytes 598 cells per microliter, and 96% had plasma HIV-1 RNA <50 copies per milliliter. Low- and high-function subjects had similar CD4(+) lymphocyte count and duration and type of antiretroviral therapy. Lower T scores at the hip [OR: 3.8 (1.1 to 12.5)] and lumbar spine [OR: 2.3 (1.1 to 4.5)] and lower lean body mass [OR: 1.1 (1.0 to 1.2)] were associated with significantly greater odds of low function (P ≤ 0.03). Lower insulin-like growth hormone [IGF-1; OR: 5.0 (1.4 to 20.0)] and IGF-1 binding protein-3 [OR: 3.3 (1.7 to 9.9)] increased the odds of low functional status (P ≤ 0.02). Fat mass and lower 25-OH vitamin D did not increase the odds of low functional status (P > 0.05). CONCLUSIONS: Functional impairment in HIV-1-infected persons on successful antiretroviral therapy is associated with low muscle mass, low bone mineral density, and low IGF-1 and IGF-1 binding protein-3. These characteristics may be a manifestation of early "somatopause" in middle-aged HIV-infected adults.
BACKGROUND:Disability and frailty are associated with osteoporosis, obesity, and sarcopenia. HIV-infectedpersons have early functional impairment, but the association between body composition and functional impairment is unknown. METHODS:HIV-1-infectedparticipants on combination antiretroviral therapy with virologic suppression, aged 45-65 years, had standardized physical function measures. In a nested analysis, 30 low- and 48 high-functioning cases and controls were matched by age, gender, and time since HIV diagnosis. Bone mineral density, fat mass, and lean body mass were assessed by dual-energy x-ray absorptiometry. Odds ratios (ORs) with 95% confidence intervals were obtained from conditional logistic regression. RESULTS: Mean age was 53 years, mean CD4(+) lymphocytes 598 cells per microliter, and 96% had plasma HIV-1 RNA <50 copies per milliliter. Low- and high-function subjects had similar CD4(+) lymphocyte count and duration and type of antiretroviral therapy. Lower T scores at the hip [OR: 3.8 (1.1 to 12.5)] and lumbar spine [OR: 2.3 (1.1 to 4.5)] and lower lean body mass [OR: 1.1 (1.0 to 1.2)] were associated with significantly greater odds of low function (P ≤ 0.03). Lower insulin-like growth hormone [IGF-1; OR: 5.0 (1.4 to 20.0)] and IGF-1 binding protein-3 [OR: 3.3 (1.7 to 9.9)] increased the odds of low functional status (P ≤ 0.02). Fat mass and lower 25-OH vitamin D did not increase the odds of low functional status (P > 0.05). CONCLUSIONS:Functional impairment in HIV-1-infectedpersons on successful antiretroviral therapy is associated with low muscle mass, low bone mineral density, and low IGF-1 and IGF-1 binding protein-3. These characteristics may be a manifestation of early "somatopause" in middle-aged HIV-infected adults.
Authors: S E Mulroney; K J McDonnell; C B Pert; M R Ruff; Z Resch; W K Samson; M D Lumpkin Journal: Proc Natl Acad Sci U S A Date: 1998-02-17 Impact factor: 11.205
Authors: W Jack Rejeski; Roger A Fielding; Steven N Blair; Jack M Guralnik; Thomas M Gill; Evan C Hadley; Abby C King; Stephen B Kritchevsky; Michael E Miller; Anne B Newman; Marco Pahor Journal: Contemp Clin Trials Date: 2005-04 Impact factor: 2.226
Authors: Jane A Cauley; Li-Yung Lui; Kristine E Ensrud; Joseph M Zmuda; Katie L Stone; Marc C Hochberg; Steven R Cummings Journal: JAMA Date: 2005-05-04 Impact factor: 56.272
Authors: Julia H Arnsten; Ruth Freeman; Andrea A Howard; Michelle Floris-Moore; Nanette Santoro; Ellie E Schoenbaum Journal: Clin Infect Dis Date: 2006-02-24 Impact factor: 9.079
Authors: Krisann K Oursler; Ali Iranmanesh; Chani Jain; Kim L Birkett; Brandon C Briggs; Dorothy C Garner; John D Sorkin; Alice S Ryan Journal: AIDS Res Hum Retroviruses Date: 2019-12-23 Impact factor: 2.205
Authors: Kellie L Hawkins; Long Zhang; Derek K Ng; Keri N Althoff; Frank J Palella; Lawrence A Kingsley; Lisa P Jacobson; Joseph B Margolick; Jordan E Lake; Todd T Brown; Kristine M Erlandson Journal: AIDS Date: 2018-06-19 Impact factor: 4.177
Authors: Kristine M Erlandson; Amanda A Allshouse; Eric Rapaport; Brent E Palmer; Cara C Wilson; Adriana Weinberg; Samantha MaWhinney; Thomas B Campbell Journal: AIDS Res Hum Retroviruses Date: 2015-07-08 Impact factor: 2.205
Authors: Meredith Greene; Kenneth Covinsky; Jacquie Astemborski; Damani A Piggott; Todd Brown; Sean Leng; Noya Galai; Shruti H Mehta; Jack Guralnik; Kushang V Patel; Gregory D Kirk Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Philip M Grant; Douglas Kitch; Grace A McComsey; Ann C Collier; Benedetta Bartali; Susan L Koletar; Kristine M Erlandson; Jordan E Lake; Michael T Yin; Kathy Melbourne; Belinda Ha; Todd T Brown Journal: AIDS Date: 2016-11-28 Impact factor: 4.177